Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
ID: HT9402-25-Q-9102Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f4bb38e3b231424dadb1175bc4d5daad/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.

    Point(s) of Contact
    Tracy Banks
    tracy.e.banks2.civ@mail.mil
    Julia Trang
    julia.n.trang.civ@health.mil
    Files
    Title
    Posted
    DoD Formulary Placement of FDA Newly Approved Drugs.pdf
    The document outlines the process for the formulary placement of newly approved innovator drugs within the Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/TRICARE Pharmacy Benefits Program, following the Final Rule published on July 27, 2015. The Pharmacy and Therapeutics (P&T) Committee is responsible for evaluating these drugs, classified under various chemical types, and has up to 120 days to recommend their tier placement on the uniform formulary. Newly approved drugs after August 26, 2015, will initially hold a pending status and will be reviewed quarterly for placement, considering clinical and cost-effectiveness. Prices must be available 30 days prior to meetings to avoid deferrals. Manufacturers can submit price concessions during specified solicitation windows, with drugs being categorized from Tier 1 to Tier 4/Not Covered based on the Committee's evaluations. Tier 3 designation generally limits these drugs' availability, except in cases where medical necessity is proven. The document emphasizes the structured approach to drug assessment, highlighting the Department of Defense’s efforts to ensure effective drug management in military healthcare.
    Price Appendix FAQ NAD.pdf
    The document outlines the procedures and requirements for submitting quotes for various drug-related categories within a government context. It provides detailed instructions for three main pricing frameworks: BPA (basic pricing agreements), ADP (non-FAMP and WAC discounts). Each section emphasizes the importance of filling in specified fields, indicated with yellow cells, and highlights how certain inputs auto-populate related fields, streamlining the data submission process. Key points include the necessity of understanding the P&T committee’s formulary decision-making process, the importance of correctly entering pricing information for National Drug Codes (NDCs), and the implications of submitting zero discounts, which will be flagged for the committee’s attention. Furthermore, it outlines guidelines for submitting more than the initial 10 NDCs by contacting designated points of contact. Overall, the document serves as a comprehensive guide for vendors seeking to participate in federal drug procurement, ensuring adherence to specific data entry protocols and emphasizing the significance of accurate pricing information in the context of governmental requests for proposals (RFPs). It aims to facilitate efficient bid submissions while maintaining compliance with federal standards and formularies.
    Price List - Itovebi - Oncological Agents - Breast Cancer.xlsx
    The document outlines the upcoming Pharmaceutical and Therapeutics (P&T) Committee Meeting scheduled for February 5-6, 2025, focusing on oncological agents specifically for breast cancer. It sets a deadline for quotes from manufacturers for newly approved drugs by December 19, 2024. The document details the approval process governed by the Department of Defense (DOD) Uniform Formulary, where drugs may be categorized as uniform or non-formulary based on specific pricing and usage criteria. Key elements include price per National Drug Code (NDC) and dosage forms, along with conditions for potential discounts through programs like TRICARE Retail Refund. The P&T Committee evaluates drugs for potential high-value status and may recommend exclusions from the TRICARE pharmacy benefit program. Essential procedural notes and conditions regarding prior authorization, step therapy, and manufacturers' responsibilities in submitting documentation are emphasized. The document serves as a guide for suppliers intending to engage with the Department of Defense’s formulary system, ensuring transparency and compliance with federal regulations for the procurement of oncological drugs.
    Price List - Miplyffa - Neurological Agents Miscellaneous - NA.xlsx
    The document pertains to the Department of Defense (DoD) Uniform Formulary for Neurological Agents Miscellaneous, presented for the P&T Committee meeting scheduled for February 5-6, 2025. It outlines the process for suppliers to submit quotes for newly approved drugs, with a submission deadline set for December 19, 2024. The document describes the requirement for submitted quotes to include specific details such as National Drug Code (NDC) number, drug name, strength, dosage form, and package size, while cautioning that lack of submission may highlight a company's intent not to participate. Additionally, it emphasizes that these agents may require prior authorization and may be eligible for special reimbursement methods aimed at encouraging the use of high-value products. The P&T Committee has the authority to recommend preferential treatment for certain non-generic pharmaceutical agents and can also identify drugs for exclusion from the TRICARE pharmacy benefit program. The overarching purpose of the document is to guide manufacturers in navigating the formulary submission process while ensuring compliance with the DoD's pharmaceutical procurement criteria, ultimately supporting the military healthcare system's drug formulary management.
    Price List - Opipza - Antipsychotic Agents - Atypical.xlsx
    The document outlines the upcoming Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee meeting scheduled for February 5-6, 2025, focusing on antipsychotic agents, specifically atypical agents. It details a timeline for submitting quotes by December 19, 2024, for newly approved drugs, along with certain stipulations for the manufacturers. The proposal includes various scenarios emphasizing the need for price quotations for Uniform and Non-Formulary drugs, indicating that no quotes have been received thus far. The additional discount program appendices detail TRICARE retail refunds and requirements for submission, stressing the importance of confirming intent to quote. The document specifies that a prior authorization (PA) may be applicable for agents reviewed. The main goal is to facilitate contracts for pharmaceuticals while evaluating their reimbursement methods, promoting high-value products, and potentially altering their formulary status based on cost-sharing strategies. Overall, the document highlights the structured approach to enhancing DoD pharmacy services amidst regulatory standards aimed at ensuring effective healthcare support for its members.
    RFQ HT9402-25-Q-9102 NAD.pdf
    The Department of Defense (DoD) has issued a Request for Quotation (RFQ) related to the procurement of pharmaceutical agents for the Military Health System via the Defense Health Agency and the Pharmacy and Therapeutics Committee. This RFQ outlines the process by which pharmaceutical companies can submit price quotes for agents to be included in the Uniform Formulary (UF), which classifies drugs into tiers based on cost-effectiveness and clinical efficacy. Key components include instructions for quote submissions, government-provided data, and criteria for evaluating and awarding Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP). Companies must provide comprehensive pricing information, including National Drug Code (NDC) lists, and adhere to strict regulations regarding the inclusion of their pharmaceuticals in designated formularies. The document underscores the importance of compliance and transparency in pricing, with final approvals contingent upon evaluations by the DoD Pharmacy and Therapeutics Committee. The overarching goal is to ensure an effective and cost-efficient pharmacy benefits program for military health beneficiaries while facilitating competitive pricing from manufacturers.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Military Treatment Facilities (MTFs) and TRICARE pharmacies. This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs, which will be evaluated by the Pharmacy and Therapeutics (P&T) Committee. Key drugs under consideration include newly approved agents for lung cancer, antihypertensive agents, oncological agents, diuretics, antilipidemics, and targeted immunomodulatory biologics, with quotes due by January 5, 2026, for a committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Tracy Banks or Julia Trang via email for further details and ensure compliance with submission requirements outlined in the RFQ document HT9402-26-Q-9103.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for Trazodone HCL tablets in various dosages and bottle counts. This procurement aims to fulfill substantial pharmaceutical supply needs, emphasizing compliance with technical and quality requirements as outlined in the solicitation documents. The solicitation, identified as SPE2D2-26-R-0003, mandates electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal acquisition regulations and ethical standards. Metaxalone is a critical medication used for muscle relaxation, making this contract vital for supporting military health services. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST. For further inquiries, contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.
    DLA MedSurg Prime Vendor Gen VI
    Dept Of Defense
    The Defense Logistics Agency (DLA) is seeking proposals for the Medical Surgical Prime Vendor (Med/Surg PV) Program, which aims to provide a comprehensive range of medical and surgical supplies across three Global Regions: North, South, and West. This procurement involves awarding Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for both Primary and Backup Prime Vendors, facilitating routine ordering and contingency support for various military and federal healthcare facilities. The program is critical for ensuring the availability of essential medical supplies and equipment, supporting the operational readiness of Medical Treatment Facilities (MTFs) and clinics worldwide. Interested vendors must submit their proposals electronically via the DLA Internet Bid Board System (DIBBS) by January 8, 2026, at 3:00 PM Local Philadelphia Time, and can direct inquiries to Beatrice Lopez-Pollard at beatrice.lopez-pollard@dla.mil or Joshua Tankel at Joshua.Tankel@dla.mil.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Tretinoin Cream
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Tretinoin Cream. The cream is used for various dermatological conditions and comes in different strengths (0.025%, 0.05%, and 0.1%) and tube sizes (20G and 45G). The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. It will establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. Interested parties should contact Ryan Ferry for more information. The projected solicitation date is February 2023.